Top-line results are expected later this month.| Sleep Review
Alkermes’ alixorexton met primary and key secondary endpoints in a phase 2 trial for narcolepsy type 1, showing dose-dependent improvements.| Sleep Review
Buntanetap lowered amyloid-beta and tau levels in people with early Alzheimer's disease and its developer Annovis Bio is planning more trials.| Alzheimer's News Today